ADPT · Adaptive Biotechnologies Corp
Price
Snapshot
50 fields · last close| Market Cap | $4.52B |
| P/E | — |
| Float | 156.5M |
| Beta | 2.16 |
| Volatility | 54.0% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | 60.3 |
| Price | 28.35 |
| Change | +0.00% |
| Prev Close | 28.35 |
| Open | 27.59 |
| Day Low | 27.31 |
| Day High | 28.41 |
| Avg Vol | 3 |
| Avg $ Vol | $73.95M |
| 52W High | 29.96 |
| 52W Low | 12.00 |
| 52W Pos | 91.0% |
| From High | −5.37% |
| From Low | +136.25% |
| Max DD 1Y | −39.35% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +4.52% |
| SMA 50 | +10.78% |
| SMA 200 | +51.94% |
| RSI (14) | 58.5 |
| Vol 30D | 44.2% |
| Vol 90D | 61.0% |
| 1Y Range | 12–30 |
| Daily bars | 900 |
| Perf Week | −3.67% |
| Perf Month | +14.96% |
| Perf Quarter | +31.86% |
| Perf Half Y | +91.42% |
| Perf Year | +94.71% |
| Perf YTD | +78.19% |
| Prev Day | +0.00% |
| Clavix | C |
| Debt / Eq | 0.60 |
| Curr Ratio | 3.34 |
| Int Cover | -21.9× |
| FCF Margin | −17.7% |
| Rev Growth | +54.8% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 16 / 19 |
Clavix risk grade
regraded every trading dayADPT grades C, 60.3 of 100. Steadiest on News Sentiment (66), most exposed on Price Stability (43, fragile). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 16 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| ADPT | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.16 | 1.18 |
| Volatilityannualized | 54.0% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −39.3% | — |
| Typical daily movemedian absolute daily change | 2.01% | — |
| Days beyond ±3%of the last 252 sessions | 90 (36%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ADPT | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.16 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ADPT | |
|---|---|
| 1 week | −3.7% |
| 1 month | +15.0% |
| Year to date | +78.2% |
| 1 year | +94.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ADPT | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 23 since 21 Jul |
| Average score0 most bearish, 100 most bullish | 61 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 5 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| ADPT | |
|---|---|
| Revenue growthyear over year | +54.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openGoldman Sachs began covering Adaptive Biotechnologies on Tuesday, assigning it a 'buy' rating with a $35.00 price target.
Adaptive Biotechnologies said its highly sensitive minimal residual disease (MRD) testing was included in a new international consensus definition of cure for multiple myeloma, presented at the International Myeloma Society's annual meeting in Glasgow on September 25, 2026.
Adaptive Biotechnologies said a new international consensus definition of 'cure' for multiple myeloma requires five years off treatment with sustained MRD negativity, measured by a test sensitive enough to detect one myeloma cell among one million cells.
The National Comprehensive Cancer Network (NCCN) updated its multiple myeloma treatment guidelines to more fully include minimal residual disease (MRD) testing, checking for tiny remaining traces of cancer after treatment, and explicitly named Adaptive Biotechnologies' clonoSEQ diagnostic test. Shares rose 6%. No specific catalyst was identified.
Adaptive Biotechnologies said updated cancer treatment guidelines from the National Comprehensive Cancer Network (NCCN) now specifically name the company's clonoSEQ blood test for multiple myeloma and recommend testing at more points during a patient's care. The new recommendations call for clonoSEQ testing once a year during the ongoing 'maintenance' phase (lower-dose treatment meant to keep the cancer from coming back) and after later rounds of treatment.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| QGEN | Qiagen NV | B+ | $9.22B | 22.53 | 0.59 | Compare |
| BRKR | Bruker Corp | C | $9.64B | — | 1.24 | Compare |
| RGEN | Repligen Corp | B- | $10.25B | 246.86 | 1.13 | Compare |
| AVTR | Avantor Inc | B- | $10.38B | — | 0.98 | Compare |
| TECH | Bio-Techne Corp | B | $11.35B | 62.43 | 1.29 | Compare |
| TXG | 10X Genomics Inc | C- | $12.18B | — | 2.01 | Compare |
| TEM | Tempus AI Inc | D- | $13.83B | — | 2.25 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $13.85B | — | 1.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.